Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines

Cancer is one of the leading causes of morbidity and mortality in the pediatric population with the most common Cancer being acute lymphoblastic leukemia. One of the most common drugs used in the treatment is the anthracycline group of chemotherapeutic agents, and a major side effect is cardiotoxicity. Dexrazoxane, a member of the cardioprotective agents' group of medications, is the only current FDA-approved medication to tackle cardiotoxicity. The mechanism of action in which dexrazoxane is cardioprotective is by halting Necroptosis in cardiomyocytes after anthracycline therapy and concurrently binds with iron and reduces the formation of anthracycline-iron complexes and Reactive Oxygen Species. The efficacy of dexrazoxane has been demonstrated in clinical trials within the pediatric population with roughly 60%-80% reduction in risk of developing cardiotoxicity with a very tolerable and limited side effect profile. Further research is required to not only establish the efficacy of dexrazoxane within the pediatric population but also to explore other medications that may serve alongside the function of dexrazoxane.

anthracycline-induced cardiomyopathy; chemotherapy-related toxicity; dexrazoxane; pediatric cancer; pediatrics cardiotoxicity.